Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BEAMNASDAQ:MIRMNASDAQ:VALNNASDAQ:VCEL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBEAMBeam Therapeutics$19.56-11.9%$26.65$18.32▼$35.25$1.97B1.911.30 million shs4.61 million shsMIRMMirum Pharmaceuticals$45.03-2.1%$48.01$23.14▼$54.23$2.21B1.04519,559 shs186,330 shsVALNValneva$6.78-6.6%$6.63$3.62▼$9.50$554.20M1.9326,238 shs22,398 shsVCELVericel$44.56+0.1%$53.23$39.12▼$63.00$2.23B1.78377,356 shs191,453 shs7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBEAMBeam Therapeutics0.00%-4.68%-15.68%-12.11%-32.78%MIRMMirum Pharmaceuticals0.00%-2.19%-3.32%+11.68%+83.08%VALNValneva0.00%+1.26%+7.56%+68.06%-8.33%VCELVericel0.00%-3.80%-13.24%-19.53%-14.46%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBEAMBeam Therapeutics3.1875 of 5 stars4.51.00.00.03.02.50.6MIRMMirum Pharmaceuticals4.3747 of 5 stars3.52.00.04.23.53.30.6VALNValneva1.798 of 5 stars3.53.00.00.01.80.80.0VCELVericel3.1539 of 5 stars3.53.00.00.03.00.81.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBEAMBeam Therapeutics 3.00Buy$49.45152.80% UpsideMIRMMirum Pharmaceuticals 3.09Buy$58.2029.24% UpsideVALNValneva 3.00Buy$16.00135.99% UpsideVCELVericel 3.00Buy$62.2939.78% UpsideCurrent Analyst Ratings BreakdownLatest VALN, BEAM, VCEL, and MIRM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/31/2025VALNValnevaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$17.00 ➝ $17.003/28/2025BEAMBeam TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$42.00 ➝ $42.003/24/2025VALNValnevaGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$17.00 ➝ $15.003/21/2025VALNValnevaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$17.00 ➝ $17.003/12/2025BEAMBeam TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight3/10/2025BEAMBeam TherapeuticsJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy$34.003/10/2025BEAMBeam TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$80.00 ➝ $80.003/10/2025BEAMBeam TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$57.003/10/2025BEAMBeam TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeSector Perform ➝ Sector Outperform$40.003/3/2025BEAMBeam TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Perform ➝ Sector Perform$24.00 ➝ $25.003/3/2025VCELVericelTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$67.00 ➝ $61.00(Data available from 3/31/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBEAMBeam Therapeutics$63.52M30.73N/AN/A$12.04 per share1.62MIRMMirum Pharmaceuticals$336.89M6.55N/AN/A$5.33 per share8.45VALNValneva$169.58M3.25N/AN/A$2.00 per share3.39VCELVericel$237.22M9.42$0.01 per share3,081.95$4.73 per share9.42Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBEAMBeam Therapeutics-$132.53M-$4.58N/AN/AN/A-41.07%-16.22%-10.94%5/6/2025 (Estimated)MIRMMirum Pharmaceuticals-$163.41M-$1.85N/AN/AN/A-31.69%-41.22%-14.81%5/6/2025 (Estimated)VALNValneva-$109.78M-$0.17N/AN/AN/A-4.35%-3.93%-1.42%5/6/2025 (Estimated)VCELVericel-$3.18M$0.18741.46101.27N/A1.56%1.48%0.96%5/6/2025 (Estimated)Latest VALN, BEAM, VCEL, and MIRM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/20/2025Q4 2024VALNValneva-$0.22-$0.54-$0.32-$0.54$55.64 million$56.48 million2/26/2025Q4 2024MIRMMirum Pharmaceuticals-$0.27-$0.49-$0.22-$0.49$96.64 million$99.41 million2/25/2025Q4 2024BEAMBeam Therapeutics-$1.25-$1.09+$0.16-$1.09$16.47 million$30.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBEAMBeam Therapeutics$0.904.60%N/AN/A N/AMIRMMirum PharmaceuticalsN/AN/AN/AN/AN/AVALNValnevaN/AN/AN/AN/AN/AVCELVericelN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBEAMBeam TherapeuticsN/A5.695.69MIRMMirum Pharmaceuticals1.333.343.15VALNValneva0.702.782.25VCELVericelN/A4.614.23Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBEAMBeam Therapeutics99.68%MIRMMirum PharmaceuticalsN/AVALNValneva11.39%VCELVericelN/AInsider OwnershipCompanyInsider OwnershipBEAMBeam Therapeutics4.20%MIRMMirum Pharmaceuticals22.87%VALNValneva14.91%VCELVericel5.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBEAMBeam Therapeutics51099.79 million79.33 millionOptionableMIRMMirum Pharmaceuticals14049.01 million37.03 millionOptionableVALNValneva70081.26 million69.15 millionNot OptionableVCELVericel30050.14 million46.79 millionOptionableVALN, BEAM, VCEL, and MIRM HeadlinesRecent News About These CompaniesWINTON GROUP Ltd Sells 8,900 Shares of Vericel Co. (NASDAQ:VCEL)March 31 at 4:20 AM | marketbeat.comPremier Fund Managers Ltd Sells 7,383 Shares of Vericel Co. (NASDAQ:VCEL)March 30 at 5:53 AM | marketbeat.comSegall Bryant & Hamill LLC Lowers Stock Position in Vericel Co. (NASDAQ:VCEL)March 29 at 4:44 AM | marketbeat.comWhich Is a Better Investment, Alvotech or Vericel Corporation Stock?March 28 at 5:12 PM | aaii.comVericel Co. (NASDAQ:VCEL) Holdings Cut by Loomis Sayles & Co. L PMarch 28 at 6:49 AM | marketbeat.comAn Intrinsic Calculation For Vericel Corporation (NASDAQ:VCEL) Suggests It's 47% UndervaluedMarch 27, 2025 | finance.yahoo.comVericel Co. (NASDAQ:VCEL) Shares Bought by Zions Bancorporation N.A.March 27, 2025 | marketbeat.comEFG Asset Management North America Corp. Purchases 48,295 Shares of Vericel Co. (NASDAQ:VCEL)March 26, 2025 | marketbeat.comCongress Wealth Management LLC DE Raises Stock Position in Vericel Co. (NASDAQ:VCEL)March 26, 2025 | marketbeat.comSwiss National Bank Has $5.30 Million Holdings in Vericel Co. (NASDAQ:VCEL)March 25, 2025 | marketbeat.comKnights of Columbus Asset Advisors LLC Grows Stock Holdings in Vericel Co. (NASDAQ:VCEL)March 24, 2025 | marketbeat.comSummit Global Investments Sells 8,663 Shares of Vericel Co. (NASDAQ:VCEL)March 24, 2025 | marketbeat.comVericel Co. (NASDAQ:VCEL) Given Consensus Rating of "Buy" by AnalystsMarch 24, 2025 | marketbeat.comVericel Co. (NASDAQ:VCEL) Shares Sold by Thrivent Financial for LutheransMarch 22, 2025 | marketbeat.comProficio Capital Partners LLC Invests $956,000 in Vericel Co. (NASDAQ:VCEL)March 22, 2025 | marketbeat.comAmundi Boosts Stock Holdings in Vericel Co. (NASDAQ:VCEL)March 19, 2025 | marketbeat.comCharles Schwab Investment Management Inc. Buys 17,258 Shares of Vericel Co. (NASDAQ:VCEL)March 19, 2025 | marketbeat.comVericel Co. (NASDAQ:VCEL) Shares Bought by William Blair Investment Management LLCMarch 18, 2025 | marketbeat.comDominick Colangelo Sells 26,592 Shares of Vericel Co. (NASDAQ:VCEL) StockMarch 15, 2025 | marketbeat.comVericel Co. (NASDAQ:VCEL) CEO Sells $1,217,381.76 in StockMarch 15, 2025 | insidertrades.comRaymond James Financial Inc. Acquires Shares of 512,219 Vericel Co. (NASDAQ:VCEL)March 15, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeVALN, BEAM, VCEL, and MIRM Company DescriptionsBeam Therapeutics NASDAQ:BEAM$19.56 -2.65 (-11.92%) As of 03:55 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.Mirum Pharmaceuticals NASDAQ:MIRM$45.03 -0.96 (-2.08%) As of 03:55 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.Valneva NASDAQ:VALN$6.78 -0.48 (-6.61%) As of 03:55 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is based in Saint-Herblain, France.Vericel NASDAQ:VCEL$44.56 +0.06 (+0.13%) As of 03:55 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 Buyable Stocks With Solid Bottoms Ready to Rebound Game-Changing News for Advanced Micro Devices Casey’s General Stores Insider Buys Shares of This Must-Own Stock U.S. Steel and Nippon Merger: Should Investors Bet on It? MarketBeat Week in Review – 03/24 - 03/28 JPMorgan: The 'NVIDIA of Banking' Poised for More Gains? Lululemon Pulls Back Into Classic Dip-Buying Opportunity Should You Buy UPS Stock Now? Deep Dive Into Its 5-Year Low Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
